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Worldwide an estimated 240 million people are 
chronically infected with chronic hepatitis B virus 
(CHB), of whom an estimated 3.4 million are co- 
infected with HIV.[1] Chronic liver disease has emerged 
as an important cause of morbidity in the HIV-infected 
population. It is, after opportunistic infections, the second most common 
cause of death among some populations of HIV-infected patients on 
antiretroviral therapy (ART).[2] In resource-limited settings (RLSs), 
infection with HIV and hepatitis B virus (HBV) is associated with 
poorer outcomes than HBV mono-infection. Co-infection is associated 
with higher rates of HBV persistence after acute infection, and among 
individuals with CHB, higher HBV DNA levels, a higher prevalence 
of HBV e antigenaemia, and an increased risk of progression to 
fibrosis, cirrhosis and possibly hepatocellular carcinoma (HCC).[2,3] 
Identifying patients who are chronically infected and providing specific 
management improves outcomes.[4] However, screening for active HBV 
infection before starting ART is not currently part of HIV guidelines in 
many countries in sub-Saharan Africa (SSA).
Epidemiology
Much of SSA has been considered to have high endemicity of CHB 
(≥8%). In Zimbabwe prevalence rates as high as 25% in an antenatal 
cohort, and rates of 13% in Malawi, 10.6% in Botswana and 17.3% in 
HIV-infected adults in Tanzania, have been reported. However, more 
recent data suggest that the prevalence in SSA may be lower than 
previously thought, probably owing to wide variations in prevalence 
across countries; for example, in South Africa (SA) the prevalence of 
hepatitis B surface antigen (HBsAg) as a marker of active HBV infection 
ranges from 3.5% to 23%.[5-7] Nevertheless, the morbidity coupled with 
the overall high endemicity of CHB is reason to screen for this infection 
and initiate optimal management for those found to be infected.
Goals of treatment and drug therapy
The primary goal of treating CHB is to reduce the risk of progressive 
liver disease, cirrhosis and HCC by suppressing HBV replication. The 
management cascade starts with diagnosing CHB by testing for HBsAg. 
This can be done by rapid point-of-care assays. If HBsAg is persistently 
detectable in the blood for >6 months, the patient is diagnosed with CHB. 
In patients positive for HBsAg, additional testing may include hepatitis B e 
antigen (HBeAg), antibody to hepatitis B e antigen (anti-HBe), and HBV 
DNA qualitatively and quantitatively. Intermediate goals and markers of 
treatment success are suppression of HBV replication as measured by the 
HBV viral load, HBeAg/anti-HBe seroconversion (in HBeAg-positive 
patients), HBsAg/anti-HBs seroconversion (preceded by a reduction in 
HBsAg titre), alanine aminotransferase normalisation and improvement 
of liver histological features. Viral eradication is not currently a goal of 
therapy, as none of the available therapeutic agents clear the highly stable 
covalently closed circular DNA (cccDNA) from hepatocytes.
A number of agents are available for the treatment of CHB, of which 
some also have HIV activity. A reverse transcriptase step in the HBV 
lifecycle, whereby pregenomic HBV RNA is transcribed to viral DNA, is 
the explanation for this. Screening for HIV in the HBV-infected patient 
before starting ART is therefore critical to avoid inadequate HIV therapy.
Tenofovir is among the most potent and effective agents for treating 
CHB. Lamivudine also has activity against HBV, but is less potent and has 
a high rate of failure and resistance development when used as a single 
HBV-active agent.[8] Entecavir also has potent activity against HBV but 
minimal activity against HIV. It is generally the treatment of choice when 
renal impairment makes tenofovir use problematic. Although available 
in SA, it is prohibitively expensive. Other HBV-specific agents have been 
developed (telbivudine, adefovir), but they are expensive, have a poorer 
resistance profile and are not widely available. Daily interferon (IFN) or 
weekly pegylated IFN therapy to treat and potentially clear HBsAg (but not 
cccDNA) is a treatment option in the mono-infected patient. However, it 
achieves lower rates of HBeAg seroconversion among co-infected patients, 
especially in the HBV genotypes common in SA, and is poorly tolerated.
Risks and benefits of treating CHB should be assessed before initiating 
therapy. Among co-infected patients who are eligible for ART, ART 
should always include HBV-active agents – ideally tenofovir. There is 
probably a subset of CHB patients with a low risk of progressive liver 
disease. Patients who are HBeAg-negative, have low HBV viral loads 
and lack evidence of liver fibrosis may not benefit from treatment. It is 
notable that the use of transaminases for monitoring liver disease, which 
assists in assessing treatment need among HIV-uninfected individuals, 
may have limited value in HIV infection because of lower transaminase 
values despite ongoing necroinflammatory disease and fibrosis. Any 
HBV-infected patient with cirrhosis or stigmata of chronic liver disease 
should receive antiviral therapy. All HIV/HBV co-infected patients with 
any evidence of liver disease (elevated transaminase levels, elevated HBV 
DNA titres, necroinflammation and fibrosis on biopsy) should be started 
on HBV-active therapy irrespective of CD4 count.[9] The most recent 
SA HIV treatment guidelines (December 2014) include known HBV 
infection as an indication to start ART, irrespective of CD4 count.
Addressing other risks
Lifestyle modifications such as reducing or curtailing alcohol intake will 
minimise the additional risk of cirrhosis. Advice about avoiding over-the-
counter herbal remedies and traditional medications is important. The 
metabolic syndrome is associated with both HIV and the development 
of non-alcoholic steatohepatitis (NASH). NASH may lead to cirrhosis 
and HCC. Risk factors for NASH and advanced fibrosis in the HBV 
mono-infected patient are age, diabetes, obesity, exposure to stavudine, 
and the metabolic syndrome. Vaccination against hepatitis A is indicated 
in those who are non-immune. The cirrhotic patient requires additional 
intervention and surveillance, e.g. gastroscopy.
Monitoring, managing and stopping 
HBV therapy
After initiation of agents active against HBV in the HIV/HBV 
co-infected patient, HBV DNA levels decline far more gradually 
than HIV RNA levels. If HBV DNA monitoring is available, it is 
reasonable to perform a test after 12 months of therapy. If there 
is failure to achieve HBV suppression by 12 months despite good 
adherence suggested by undetectable HIV RNA, entecavir added to 
tenofovir-containing therapy may result in better HBV control. Cost-
effective and practical methods for monitoring HBV DNA that will 
be valuable in RLSs, such as point-of-care HBV viral load tests and 
testing of dried blood spots, are under development.
Following initiation of ART, transaminase levels commonly increase 
transiently among co-infected patients. This is usually attributed to drug-
induced hepatotoxicity, but other causes should be considered (Table 1). 
The reported incidence of ART-related hepatotoxicity is between 5% and 
10% in the HIV-infected population, with a higher rate in co-infected 
patients.[9] Some agents, particularly nevirapine, are more likely to cause 
hepatotoxicity than others and should be avoided in patients with liver 
disease. Lopinavir/ritonavir given at higher doses in the presence of 
rifampicin-containing antituberculosis medication may induce mild to 
moderate hepatotoxicity. Most episodes are brief, lasting around 2 - 4 
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weeks, and resolve without intervention. Discontinuation of ART may be 
another cause of liver inflammation, either as part of a regimen change 
or through a lapse in adherence. Stopping HBV-active ART can lead to a 
rapid rise in HBV replication, leading to symptoms that can range from 
subclinical to fulminant hepatitis, and may mimic acute HBV infection. 
This syndrome generally occurs several weeks to months after stopping 
therapy, but may occasionally occur within days. Drug resistance rarely 
emerges in patients on potent therapy such as tenofovir.[10]
Screening for HCC
Routine CHB management in resource-rich settings includes regular 
screening for HCC. American Association for the Study of Liver Diseases 
(AASLD) guidelines recommend an ultrasound scan of the liver every 
6 - 12 months for those at risk of developing HCC.[11] Alpha-fetoprotein 
screening at 6-monthly intervals lacks sensitivity for early HCC.[12] 
Studies on optimal screening methods, intervals and evaluations of cost-
effectiveness in HIV/HBV co-infected populations in RLSs are needed.
Occult HBV infection
Occult HBV infection is partially controlled HBV infection, usually 
associated with low levels of HBV DNA (<104 IU/mL) and an HBsAg-
negative serological profile. Antibodies to HBV core (anti-HBc) 
may or may not be present. Estimates of the prevalence of occult 
HBV infection among HIV-infected patients in Africa vary between 
2% and 85%, depending on population, study design and extent 
of immune deficiency.[13] Recovery of CD4 counts, as occurs with 
ART, can lead to the resolution of occult HBV infection. The overall 
clinical importance of occult HBV infection is unclear, and there are 
currently no guidelines that recommend screening for this condition.
HBV vaccination
HBV vaccination is routinely provided in many high-income countries for 
adults in high-risk groups. Cost, and perhaps a lack of appreciation of the 
frequency of adult HBV transmission, have discouraged implementation 
of similar programmes in many RLSs, including SA. Although there are 
few data on acute HBV infection among adults in most of SSA, infection 
can and does occur, especially among higher-risk populations. One 
study from SA reported an annual incidence of newly acquired HBV 
infection of 2.5% among young women at high risk for HIV.[14] Only 
approximately a quarter of these women had evidence of prior exposure 
(anti-HBc antibodies), leaving the majority of the population at risk of 
infection. Given this incidence of HBV, the practice of vaccinating non-
immune HIV-infected individuals would seem reasonable.
Because individuals with CD4 counts <200 cells/μL have a poor immune 
response to vaccination, vaccinating adults with higher CD4 counts is likely 
to have greater public health impact. Data are needed to better understand 
the cost-effectiveness of HBV vaccination in HIV-infected adults in RLSs.
The commencement of routine infant HBV vaccination, currently at 
6 weeks of age, should be shifted to closer to the time of birth in order 
to prevent mother-to-child transmission (MTCT) of HBV.
Conclusion
With the roll-out of ART in RLSs, the emphasis of care is shifting 
to maintaining quality of life and managing chronic conditions. 
Given the high prevalence of HBV infection in SSA and the risk of 
HIV/HBV co-infected patients developing liver complications, the 
management of HBV/HIV should be prioritised. In SSA efforts need 
to be focused on screening for chronic viral hepatitis, early institution 
of effective antiviral therapy, vaccinating those who are most at risk of 
infection, and the prevention of HBV MTCT.
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Table 1. Causes of liver enzyme elevation during ART
Drug effects – ART related and non-ART related
Poor adherence
Inadvertent stopping of anti-HBV agents, e.g. changing from first- to 
second-line ART
Infection with another agent, e.g. TB, HAV, HEV
Hepatic steatosis (associated with chronic ART use and the 
metabolic syndrome)
Toxins, e.g. alcohol and herbal medicines
Worsening of underlying liver disease, e.g. autoimmune liver disease
Emergence of HBV resistance
TB = tuberculosis; HAV = hepatitis A virus; HEV = hepatitis E virus.
